drugset / Trial / NCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Timeline
- Start
- 2024-11-12
- Primary completion
- 2026-10-28
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Comparator | Sugemalimab | Monoclonal antibody | 1200 mg | — |